当前位置: X-MOL 学术Expert Rev. Anti Infect. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine.
Expert Review of Anti-infective Therapy ( IF 4.2 ) Pub Date : 2020-05-04 , DOI: 10.1080/14787210.2020.1761333
Matthew W McCarthy 1
Affiliation  

Introduction

Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of nucleic acid that play a role in prokaryotic defense and form the basis of a genome editing technology that allows permanent alteration of genetic material. This methodology, known as CRISPR-Cas9, is poised to revolutionize molecular biology, but no literature yet exists on how these advances will affect hospitalists.

Areas covered

These specialists in inpatient medicine care for a wide variety of hospitalized patients, including those with infectious disease, cancer, cardiovascular disease, autoimmune disease, hematologic disease, and a variety of other conditions that may soon be impacted by advances in gene-modifying technology provided by CRISPR-Cas9. A Literature search was performed using PubMed [1 December 2019–17 April 2020].

Expert opinion

This paper reviews the remarkable diagnostic and therapeutic potential of the CRISPR-Cas9 platform and concludes with a look at ethical issues and technical hurdles pertaining to the implementation of permanent gene modification in the practice of Hospital Medicine.



中文翻译:

利用基于 CRISPR 的平台的潜力来推进医院医学领域的发展。

介绍

成簇的规则间隔的短回文重复序列 (CRISPR) 是在原核防御中发挥作用的核酸片段,并构成了允许遗传物质永久改变的基因组编辑技术的基础。这种被称为 CRISPR-Cas9 的方法有望彻底改变分子生物学,但目前还没有关于这些进步将如何影响住院医生的文献。

覆盖领域

这些住院医学专家为各种住院患者提供护理,包括患有传染病、癌症、心血管疾病、自身免疫性疾病、血液疾病以及可能很快受到基因修饰技术进步影响的各种其他疾病的患者。通过 CRISPR-Cas9。使用 PubMed [2019 年 12 月 1 日至 2020 年 4 月 17 日] 进行文献检索。

专家意见

本文回顾了 CRISPR-Cas9 平台卓越的诊断和治疗潜力,最后探讨了与在医院医学实践中实施永久性基因修饰相关的伦理问题和技术障碍。

更新日期:2020-05-04
down
wechat
bug